Andere Sprachen NKGen Biotech, Inc. Nyse

Aktien

A3EQS7

US65488A1016

NKGN

Markt geschlossen - Nyse Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
1,43 ^USD	+8,33 %		-11,18 %	-82,77 %

29.04.	Nkgen Biotech gibt FDA-Genehmigung des IND-Antrags (Investigational New Drug) für SNK01 NK-Zelltherapie bei Parkinson-Krankheit bekannt	CI
18.04.	NKGen Biotech, Inc. kündigt eine bevorstehende Präsentation über die SNK01 NK-Zelltherapie bei neurodegenerativen Erkrankungen auf dem 12. jährlichen Alzheimer & Parkinson Drug Development Summit an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease	29.04.
Nkgen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy in Parkinson's Disease	29.04.
NKGen Biotech, Inc. announced that it has received $0.55 million in funding from FirstFire Capital Management LLC, Meteora Capital, LLC, Glazer Capital, LLC, Meteora Strategic Capital, LLC, Sandia Investment Managment LP	29.04.
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit	25.04.
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology Annual Meeting	25.04.
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24.04.
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's and Parkinson's Drug Development Summit	19.04.
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit	18.04.
NKGen Biotech, Inc. Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summit	18.04.
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs	11.04.
NKGen Biotech, Inc. announced that it has received $5 million in funding	05.04.
NKGen Biotech, Inc. announced that it has received $0.5 million in funding from AJB Capital Investments LLC, Sandia Investment Managment LP, Diametric Capital, LP	01.04.
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's disease at the Tau2024 Global Conference	26.03.
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference	25.03.
NKGen Biotech, Inc. Presents Additional Phase 1 Clinical Trial Data in Alzheimer?s Disease At the Tau2024 Global Conference	25.03.
NKGen Biotech, Inc. announced that it expects to receive $0.33 million in funding from FirstFire Capital Management LLC	21.03.
NKGen Biotech, Inc. Announces Resignation of Sangwoo Park as Chairperson of the Board	20.03.
NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference	04.03.
NKGen Biotech, Inc. Announces Resignation of Alana Mcnulty as Director and as A Member of Audit Committee, Compensation Committee, and Nomination and Corporate Governance Committee	08.02.
Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies	07.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen NKGen Biotech, Inc. Nyse

Aktien

A3EQS7

US65488A1016

NKGN

Andere Sprachen

Filter